^
    Back
    Association details:
    Biomarker:KANK4-RAF1 fusion
    Cancer:Pancreatic Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncotarget
    Title:

    A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850

    Published date:
    04/10/2023
    Excerpt:
    Best responses included a partial response in 1 (2.9%) patient with pancreatic acinar cell carcinoma with a KANK4-RAF1 fusion...Combination therapy with riluzole and sorafenib was safe and tolerable in patients with advanced solid tumors. The partial response in a patient with a RAF1 fusion suggests that further exploration in a genomically selected cohort may be warranted.
    Secondary therapy:
    riluzole
    DOI:
    10.18632/oncotarget.28403